Cookson Peirce & Co. Inc. Grows Position in Boston Scientific Co. (NYSE:BSX)

Cookson Peirce & Co. Inc. raised its holdings in Boston Scientific Co. (NYSE:BSX) by 4.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 252,463 shares of the medical equipment provider’s stock after acquiring an additional 10,551 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Boston Scientific were worth $14,595,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Moneta Group Investment Advisors LLC raised its holdings in shares of Boston Scientific by 112,306.1% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 18,661,660 shares of the medical equipment provider’s stock valued at $863,475,000 after buying an additional 18,645,058 shares in the last quarter. Norges Bank purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $632,520,000. FMR LLC raised its holdings in shares of Boston Scientific by 6.8% during the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after buying an additional 8,045,263 shares in the last quarter. Steadfast Capital Management LP purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $138,969,000. Finally, American Century Companies Inc. raised its holdings in shares of Boston Scientific by 391.6% during the 3rd quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider’s stock valued at $172,752,000 after buying an additional 2,606,253 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX traded up $0.85 during mid-day trading on Tuesday, hitting $68.29. 3,547,642 shares of the company traded hands, compared to its average volume of 6,331,187. The stock’s fifty day moving average price is $67.05 and its 200-day moving average price is $59.52. Boston Scientific Co. has a one year low of $48.35 and a one year high of $69.21. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44. The firm has a market cap of $100.19 billion, a price-to-earnings ratio of 63.03, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same quarter in the previous year, the company posted $0.45 earnings per share. Research analysts anticipate that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Wells Fargo & Company raised their price target on Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Raymond James lifted their price objective on Boston Scientific from $67.00 to $73.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 1st. Truist Financial lifted their price objective on Boston Scientific from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Citigroup lifted their price objective on Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.50.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the sale, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,979 shares of company stock valued at $3,418,529. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.